Welcome to our dedicated page for Medtronic SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medtronic plc filings document material events, capital structure, registered securities, governance matters, and operating and financial disclosures for a medical-device company organized in Ireland. The 8-K record identifies MDT ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, alongside current reports used for company events and financial-result communications.
The filing record also includes exchange and registration status for debt securities, including a Form 25 notice tied to removal from listing and registration of a guarantor class of senior notes. These disclosures frame Medtronic's public-company obligations around equity, debt instruments, material agreements, and regulatory or clinical developments.
Filer reports proposed sale of Common stock via Form 144. The filing lists proposed dispositions of Common shares tied to restricted stock vesting and option exercises with transaction dates including 12/06/2025 and filing date 02/19/2026. Examples shown include Fidelity Brokerage Services LLC 52,524 and an individual grant-related lot of 30,568 shares.
Medtronic plc reported strong third quarter fiscal 2026 results, with revenue of $9.017 billion, up 8.7% as reported and 6.0% on an organic basis, slightly ahead of guidance.
GAAP diluted EPS was $0.89, while non-GAAP diluted EPS was $1.36, three cents above the guidance mid-point. Cardiovascular revenue rose 13.8% to $3.457 billion and Diabetes revenue grew 14.8% to $796 million, with Cardiac Ablation Solutions up 80% on strength in pulsed field ablation.
The company reiterated its FY26 organic revenue growth outlook of about 5.5% and non-GAAP EPS guidance of $5.62 to $5.66, including a possible $185 million tariff impact. Medtronic also highlighted multiple regulatory milestones, including U.S. FDA clearances for its Hugo robotic-assisted surgery system and Stealth AXiS Surgical System, CE Mark for Sphere-360, and two M&A deals in coronary, renal denervation, and structural heart.
Medtronic plc reported strong third quarter fiscal 2026 results, with revenue of $9.017 billion, up 8.7% as reported and 6.0% on an organic basis, slightly ahead of guidance.
GAAP diluted EPS was $0.89, while non-GAAP diluted EPS was $1.36, three cents above the guidance mid-point. Cardiovascular revenue rose 13.8% to $3.457 billion and Diabetes revenue grew 14.8% to $796 million, with Cardiac Ablation Solutions up 80% on strength in pulsed field ablation.
The company reiterated its FY26 organic revenue growth outlook of about 5.5% and non-GAAP EPS guidance of $5.62 to $5.66, including a possible $185 million tariff impact. Medtronic also highlighted multiple regulatory milestones, including U.S. FDA clearances for its Hugo robotic-assisted surgery system and Stealth AXiS Surgical System, CE Mark for Sphere-360, and two M&A deals in coronary, renal denervation, and structural heart.
Medtronic plc’s Chief Accounting Officer, Denise L. Blomquist, reported an automatic share withholding related to equity compensation. On 01/29/2026, 148 Ordinary Shares were withheld at $101 per share to cover taxes upon the vesting of previously reported restricted stock units.
After this tax withholding, Blomquist beneficially owns 12,306 Medtronic Ordinary Shares directly, which includes 97 shares acquired through dividend reinvestment since her last report.
Medtronic plc reported a routine insider transaction by one of its executives. The officer, listed as EVP & President Neuroscience, had 439 ordinary shares withheld on 12/15/2025 to pay taxes due when previously granted restricted stock units vested, at a price of $99.87 per share.
After this tax-withholding transaction, the reporting person directly owns 54,749 Medtronic ordinary shares. This total includes 251 shares that were acquired through dividend reinvestment since the prior report.
Medtronic executive insider reported a routine tax-related share withholding. On 12/15/2025, the company’s EVP, President MedSurg and Americas had 1,371 ordinary shares withheld at $99.87 per share to cover taxes when previously reported restricted stock units vested due to retirement eligibility. After this transaction, the executive beneficially owns 50,818 Medtronic shares, including 250 shares acquired through dividend reinvestment since the last report, all held directly.
Medtronic plc reported that its Chairman and CEO, who also serves as a director, had 1,564 ordinary shares withheld on 12/15/2025 to cover taxes due upon the vesting of previously granted restricted stock units. The transaction was coded as an “F” event and recorded at a price of $99.87 per share, indicating a tax-related withholding rather than an open-market sale. After this transaction, the reporting person beneficially owns 246,393 ordinary shares directly, which includes 832 shares acquired through dividend reinvestment since the prior report.
Medtronic plc executive reports routine tax-related share withholding. The EVP & President Cardiovascular of Medtronic plc reported a transaction dated 12/05/2025 involving 1,702 ordinary shares of Medtronic. The shares were withheld to cover taxes upon the vesting of previously granted restricted stock units, a common administrative step when equity awards vest. The transaction price listed was $101.36 per share.
After this withholding, the executive beneficially owns 34,177 Medtronic ordinary shares in direct form, which includes 264 shares acquired through dividend reinvestment since the prior report. No derivative securities transactions were reported in this filing.
The Vanguard Group has updated its ownership disclosure for Medtronic PLC. The firm reports beneficial ownership of 130,949,305 shares of Medtronic common stock, representing 10.21% of the class. Vanguard reports no sole voting power over these shares, with shared voting power over 7,668,852 shares. It has sole dispositive power over 118,346,690 shares and shared dispositive power over 12,602,615 shares.
The filing states that the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Medtronic. Vanguard indicates that its clients, including registered investment companies and other managed accounts, have the right to receive dividends or sale proceeds from these securities, and no single other person has an interest in more than 5% of the class.
Medtronic plc reported higher results for the quarter ended October 24, 2025. Net sales rose to $8,961 million from $8,403 million a year earlier, driven by growth across Cardiovascular, Neuroscience, Medical Surgical, and Diabetes, with segment sales reaching $8,926 million. Net income attributable to Medtronic increased to $1,374 million from $1,270 million, and diluted earnings per share improved to $1.07 from $0.99.
For the first six months of fiscal 2026, net sales were $17,539 million versus $16,318 million, and net income attributable to Medtronic was $2,414 million compared with $2,312 million. Operating cash flow was $2,013 million, while the company continued returning cash via dividends of $1,820 million and share repurchases of $495 million. Medtronic reduced its Italian payback accrual by $39 million, recorded as a sales benefit, and recognized a $90 million fair value loss on its Mozarc Medical investment.
On the balance sheet, cash and cash equivalents stood at $1,282 million with $7,045 million in investments. Total assets were $91,346 million, total liabilities $42,489 million, and total equity $48,857 million. Long-term debt increased to $27,680 million, including new 2.950% notes due 2031 and 4.200% notes due 2046, and the company had $1.4 billion of commercial paper outstanding.